Retatrutide Injection (LY-3437943)

Retatrutide Injection is an investigational triple-agonist drug designed for weight loss and metabolic health. It is developed by Eli Lilly and targets three key hormone pathways: GLP-1, GIP, and glucagon receptors. This combination helps regulate appetite, improve energy balance, and support fat metabolism.

Unlike standard GLP-1 treatments, Retatrutide is engineered to activate multiple receptors at once, producing greater weight reduction and improved metabolic results. Clinical studies show impressive outcomes, with participants achieving up to 24% weight loss over 48 weeks.